Advisory Services Network’s ImmunityBio IBRX Stock Holding History

Advisory Services Network’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,106	Closed	-$31.5K	–	3338
2026 Q1	$31.5K	Buy	+4,106	New	+$28.1K	﹤0.01%	2919
2025 Q4	–	Sell	-5,106	Closed	-$12.6K	–	2971
2025 Q3	$12.6K	Buy	+5,106	New	+$13.1K	﹤0.01%	3174
2024 Q1	–	Sell	-2,506	Closed	-$12.6K	–	2479
2023 Q4	$12.6K	Buy	+2,506	New	+$7.86K	﹤0.01%	2757
2023 Q2	–	Sell	-800	Closed	-$1.46K	–	2453
2023 Q1	$1.46K	Sell	800 -2,400	-75%	-$7.46K	﹤0.01%	3531
2022 Q4	$16.2K	Buy	+3,200	New	+$17.6K	﹤0.01%	2612
2022 Q2	–	Sell	-113,299	Closed	-$636K	–	1431
2022 Q1	$636K	Buy	+113,299	New	+$695K	0.02%	807
2021 Q3	–	Sell	-175	Closed	-$2K	–	2266
2021 Q2	$2K	Sell	175 -78,427	-100%	-$1.3M	﹤0.01%	3322
2021 Q1	$1.87M	Sell	78,602 -2,007	-2%	-$52K	0.07%	367
2020 Q4	$1.07M	Buy	80,609 +30,069	+59%	+$289K	0.04%	473
2020 Q3	$350K	Buy	+50,540	New	+$504K	0.02%	764

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisory Services Network's IBRX Position: Q2 2026 in Review

Advisory Services Network sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 4,106 shares — an estimated $31.5K sold.

Advisory Services Network first reported a position in IBRX in Q3 2020 and held it in 10 quarters. The position peaked at $1.87M in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Advisory Services Network reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 4,106 ImmunityBio shares in Q2 2026, an estimated $31.5K.
Advisory Services Network first reported a position in ImmunityBio in Q3 2020 and held it in 10 quarters.
Advisory Services Network's ImmunityBio position peaked at $1.87M in Q1 2021.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.